{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Allergy&page=13",
    "query": {
      "condition": "Drug Allergy",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 335,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Allergy&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Drug+Allergy&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T00:24:52.285Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04991935",
      "title": "Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis"
      ],
      "interventions": [
        {
          "name": "CC-93538",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 367,
      "start_date": "2022-08-09",
      "completion_date": "2025-08-14",
      "has_results": true,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04991935"
    },
    {
      "nct_id": "NCT06303128",
      "title": "Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Penicillin Allergy"
      ],
      "interventions": [
        {
          "name": "Amoxicillin 250 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin 62.5mg",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin 187.5mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "James Tarbox, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 380,
      "start_date": "2024-02-03",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-01",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06303128"
    },
    {
      "nct_id": "NCT04605094",
      "title": "Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo / Benralizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "12 Years to 130 Years"
      },
      "enrollment_count": 194,
      "start_date": "2020-11-12",
      "completion_date": "2022-09-13",
      "has_results": true,
      "last_update_posted_date": "2023-08-31",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Bridgeport",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04605094"
    },
    {
      "nct_id": "NCT04504955",
      "title": "CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Observational Non-Interventional Registry",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "CorEvitas",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10000,
      "start_date": "2020-07-14",
      "completion_date": "2100-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 1,
      "location_summary": "Waltham, Massachusetts",
      "locations": [
        {
          "city": "Waltham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04504955"
    },
    {
      "nct_id": "NCT02045264",
      "title": "Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "Icatibant (30 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-02-21",
      "completion_date": "2014-02-27",
      "has_results": true,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02045264"
    },
    {
      "nct_id": "NCT01681732",
      "title": "A Pilot Study of Personalized Medicine for Pediatric Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Personalized Care Plan",
          "type": "OTHER"
        },
        {
          "name": "Control Standard Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 22,
      "start_date": "2012-09",
      "completion_date": "2014-08-29",
      "has_results": false,
      "last_update_posted_date": "2017-04-04",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 1,
      "location_summary": "Hersey, Pennsylvania",
      "locations": [
        {
          "city": "Hersey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01681732"
    },
    {
      "nct_id": "NCT00456677",
      "title": "Evaluation of the Utility of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "minocycline",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York - Downstate Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "1996-06",
      "completion_date": "2007-10-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-18",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00456677"
    },
    {
      "nct_id": "NCT07816666",
      "title": "Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Platinum-sensitive Relapsed Epithelial Ovarian Cancer",
        "Platinum-sensitive Relapsed Fallopian Tube Cancer",
        "Platinum-sensitive Relapsed Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Torvutatug samrotecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 600,
      "start_date": "2026-09-24",
      "completion_date": "2031-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 26,
      "location_summary": "Anchorage, Alaska • Miami, Florida • Indianapolis, Indiana + 21 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07816666"
    },
    {
      "nct_id": "NCT02647086",
      "title": "Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        },
        {
          "name": "Metoprolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-12",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-22",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02647086"
    },
    {
      "nct_id": "NCT05269082",
      "title": "A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Drug Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2022-04-05",
      "completion_date": "2022-09-19",
      "has_results": false,
      "last_update_posted_date": "2022-09-23",
      "last_synced_at": "2026-10-31T00:24:52.285Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05269082"
    }
  ]
}